Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ
9.65
+0.13 (+1.37%)
Closed
Oct 19, 2026
Day's Range
9.5010.00
52 wk Range
6.3926.95
Financial Statements - CRVS - Corvus Pharmaceuticals Inc.
Revenue
0
Net Income
-15.28M▲ 75.5%
EBITDA
-70.00M▼ 1284.8%
Free Cash Flow
-32.97M▼ 29.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -42.97M | -27.54M | -23.40M | -32.56M | -38.63M | -43.76M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 25.18M | -36.56M | -5.20M | -9.39M | -4.59M | 37.22M |
| Pre Tax Income | -15.28M | -62.29M | -27.02M | -41.30M | -43.24M | -5.99M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -15.28M | -62.29M | -27.02M | -41.30M | -43.24M | -5.99M |
| EPS Basic | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 | -0.2 |
| EPS Diluted | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 | -0.2 |
| Basic Shares Outstanding | 78.96M | 60.98M | 48.02M | 46.55M | 41.85M | 29.47M |
| Diluted Shares Outstanding | 78.96M | 60.98M | 48.02M | 46.55M | 41.85M | 29.47M |
| Ebit | -42.97M | -27.54M | -23.40M | -32.56M | -38.63M | -43.76M |
| Ebitda | -70M | 5.90M | -23.25M | -32.22M | -38.17M | -43.12M |
| Net Income Continuous Operations | -15.28M | -62.29M | -27.02M | -41.30M | -43.24M | -5.99M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
